CD14 and cancer: Alterations of the monocyte compartment in the peripheral blood during immunotherapy have been found by other authors.3,5 Several studies support the concept that tumour-associated macrophages protect cancer cells from the antitumour immune responses.19,20 By monitoring eventual changes occurring during the treatment, we aimed to address whether FKBP51s+PD-L1+CD14 subset can act as an early marker of resistance that informs on possible intervention changes.